Cerevel Therapeutics Holdings Inc (CERE)
42.38
-0.14
(-0.33%)
USD |
NASDAQ |
May 07, 13:01
Cerevel Therapeutics Holdings Enterprise Value: 7.067B for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 7.067B |
| May 03, 2024 | 7.073B |
| May 02, 2024 | 7.080B |
| May 01, 2024 | 7.087B |
| April 30, 2024 | 7.102B |
| April 29, 2024 | 7.109B |
| April 26, 2024 | 7.058B |
| April 25, 2024 | 6.985B |
| April 24, 2024 | 6.955B |
| April 23, 2024 | 6.971B |
| April 22, 2024 | 6.991B |
| April 19, 2024 | 7.011B |
| April 18, 2024 | 6.998B |
| April 17, 2024 | 6.900B |
| April 16, 2024 | 6.847B |
| April 15, 2024 | 6.918B |
| April 12, 2024 | 6.945B |
| April 11, 2024 | 6.974B |
| April 10, 2024 | 6.993B |
| April 09, 2024 | 6.996B |
| April 08, 2024 | 7.011B |
| April 05, 2024 | 7.004B |
| April 04, 2024 | 7.004B |
| April 03, 2024 | 7.033B |
| April 02, 2024 | 7.036B |
| Date | Value |
|---|---|
| April 01, 2024 | 7.031B |
| March 28, 2024 | 7.022B |
| March 27, 2024 | 7.042B |
| March 26, 2024 | 7.038B |
| March 25, 2024 | 7.045B |
| March 22, 2024 | 7.007B |
| March 21, 2024 | 7.022B |
| March 20, 2024 | 7.027B |
| March 19, 2024 | 7.031B |
| March 18, 2024 | 7.074B |
| March 15, 2024 | 7.033B |
| March 14, 2024 | 7.016B |
| March 13, 2024 | 7.011B |
| March 12, 2024 | 6.951B |
| March 11, 2024 | 6.869B |
| March 08, 2024 | 6.836B |
| March 07, 2024 | 6.840B |
| March 06, 2024 | 6.840B |
| March 05, 2024 | 6.831B |
| March 04, 2024 | 6.807B |
| March 01, 2024 | 6.800B |
| February 29, 2024 | 6.791B |
| February 28, 2024 | 6.831B |
| February 27, 2024 | 6.846B |
| February 26, 2024 | 6.806B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.191B
Minimum
Mar 30 2021
7.326B
Maximum
Dec 28 2023
3.832B
Average
3.772B
Median
Mar 06 2023
Enterprise Value Benchmarks
| AbbVie Inc | 343.33B |
| Immunogen Inc (DELISTED) | -- |
| Bristol-Myers Squibb Co | 135.05B |
| Madrigal Pharmaceuticals Inc | 4.179B |
| Adverum Biotechnologies Inc | 124.12M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -132.66M |
| Total Expenses (Quarterly) | 139.56M |
| EPS Diluted (Quarterly) | -0.76 |
| Earnings Yield | -6.30% |